Optimization of adenoviral vector-mediated transgene expression in the canine brain in vivo, and in canine glioma cells in vitro

Marianela Candolfi, G. Elizabeth Pluhar, Kurt Kroeger, Mariana Puntel, James Curtin, Carlos Barcia, A. K M Ghulam Muhammad, Weidong Xiong, Chunyan Liu, Sonali Mondkar, William Kuoy, Terry Kang, Elizabeth A. McNeil, Andrew B. Freese, John R. Ohlfest, Peter F Moore, Donna Palmer, Phillip Ng, John D. Young, Pedro R. LowensteinMaria G. Castro

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Expression of the immune-stimulatory molecule Fms-like tyrosine kinase 3 ligand (Flt3L) and the conditional cytotoxic enzyme herpes simplex virus type 1 thymidine kinase (HSV1-TK) provides long-term immune-mediated survival of large glioblastoma multiforme (GBM) models in rodents. A limitation for predictive testing of novel antiglioma therapies has been the lack of a glioma model in a large animal. Dogs bearing spontaneous GBM may constitute an attractive large-animal model for GBM, which so far has remained underappreciated. In preparation for a clinical trial in dogs bearing spontaneous GBMs, we tested and optimized adenovirus-mediated transgene expression with negligible toxicity in the dog brain in vivo and in canine J3T glioma cells. Expression of the marker gene β-galactosidase (β-Gal) was higher when driven by the murine (m) than the human (h) cytomegalovirus (CMV) promoter in the dog brain in vivo, without enhanced inflammation. In the canine brain, β-Gal was expressed mostly in astrocytes. β-Gal activity in J3T cells was also higher with the mCMV than the hCMV promoter driving tetracycline-dependent (TetON) transgene expression within high-capacity adenovirus vectors (HC-Ads). Dog glioma cells were efficiently transduced by HC-Ads expressing mCMV-driven HSV1-TK, which induced 90% reduction in cell viability in the presence of ganciclovir. J3T cells were also effectively transduced with HC-Ads expressing Flt3L under the control of the regulatable TetON promoter system, and as predicted, Flt3L release was stringently inducer dependent. HC-Ads encoding therapeutic transgenes under the control of regulatory sequences driven by the mCMV promoter are excellent vectors for the treatment of spontaneous GBM in dogs, which constitute an ideal preclinical animal model.

Original languageEnglish (US)
Pages (from-to)245-258
Number of pages14
JournalNeuro-Oncology
Volume9
Issue number3
DOIs
StatePublished - Jul 2007

Fingerprint

Transgenes
Glioma
Canidae
Adenoviridae
Dogs
Glioblastoma
Brain
Thymidine Kinase
Human Herpesvirus 1
Animal Models
Galactosidases
Ganciclovir
Tetracycline
Cytomegalovirus
Astrocytes
In Vitro Techniques
Rodentia
Cell Survival
Clinical Trials
Inflammation

Keywords

  • Brain inflammation
  • Canine
  • Flt3L
  • Gene therapy
  • Glioma
  • Gutless adenoviral vectors
  • HSV1-TK

ASJC Scopus subject areas

  • Oncology
  • Clinical Neurology
  • Cancer Research

Cite this

Candolfi, M., Pluhar, G. E., Kroeger, K., Puntel, M., Curtin, J., Barcia, C., ... Castro, M. G. (2007). Optimization of adenoviral vector-mediated transgene expression in the canine brain in vivo, and in canine glioma cells in vitro. Neuro-Oncology, 9(3), 245-258. https://doi.org/10.1215/15228517-2007-012

Optimization of adenoviral vector-mediated transgene expression in the canine brain in vivo, and in canine glioma cells in vitro. / Candolfi, Marianela; Pluhar, G. Elizabeth; Kroeger, Kurt; Puntel, Mariana; Curtin, James; Barcia, Carlos; Muhammad, A. K M Ghulam; Xiong, Weidong; Liu, Chunyan; Mondkar, Sonali; Kuoy, William; Kang, Terry; McNeil, Elizabeth A.; Freese, Andrew B.; Ohlfest, John R.; Moore, Peter F; Palmer, Donna; Ng, Phillip; Young, John D.; Lowenstein, Pedro R.; Castro, Maria G.

In: Neuro-Oncology, Vol. 9, No. 3, 07.2007, p. 245-258.

Research output: Contribution to journalArticle

Candolfi, M, Pluhar, GE, Kroeger, K, Puntel, M, Curtin, J, Barcia, C, Muhammad, AKMG, Xiong, W, Liu, C, Mondkar, S, Kuoy, W, Kang, T, McNeil, EA, Freese, AB, Ohlfest, JR, Moore, PF, Palmer, D, Ng, P, Young, JD, Lowenstein, PR & Castro, MG 2007, 'Optimization of adenoviral vector-mediated transgene expression in the canine brain in vivo, and in canine glioma cells in vitro', Neuro-Oncology, vol. 9, no. 3, pp. 245-258. https://doi.org/10.1215/15228517-2007-012
Candolfi, Marianela ; Pluhar, G. Elizabeth ; Kroeger, Kurt ; Puntel, Mariana ; Curtin, James ; Barcia, Carlos ; Muhammad, A. K M Ghulam ; Xiong, Weidong ; Liu, Chunyan ; Mondkar, Sonali ; Kuoy, William ; Kang, Terry ; McNeil, Elizabeth A. ; Freese, Andrew B. ; Ohlfest, John R. ; Moore, Peter F ; Palmer, Donna ; Ng, Phillip ; Young, John D. ; Lowenstein, Pedro R. ; Castro, Maria G. / Optimization of adenoviral vector-mediated transgene expression in the canine brain in vivo, and in canine glioma cells in vitro. In: Neuro-Oncology. 2007 ; Vol. 9, No. 3. pp. 245-258.
@article{b1eb8939368c4659a29d2b6e2240b680,
title = "Optimization of adenoviral vector-mediated transgene expression in the canine brain in vivo, and in canine glioma cells in vitro",
abstract = "Expression of the immune-stimulatory molecule Fms-like tyrosine kinase 3 ligand (Flt3L) and the conditional cytotoxic enzyme herpes simplex virus type 1 thymidine kinase (HSV1-TK) provides long-term immune-mediated survival of large glioblastoma multiforme (GBM) models in rodents. A limitation for predictive testing of novel antiglioma therapies has been the lack of a glioma model in a large animal. Dogs bearing spontaneous GBM may constitute an attractive large-animal model for GBM, which so far has remained underappreciated. In preparation for a clinical trial in dogs bearing spontaneous GBMs, we tested and optimized adenovirus-mediated transgene expression with negligible toxicity in the dog brain in vivo and in canine J3T glioma cells. Expression of the marker gene β-galactosidase (β-Gal) was higher when driven by the murine (m) than the human (h) cytomegalovirus (CMV) promoter in the dog brain in vivo, without enhanced inflammation. In the canine brain, β-Gal was expressed mostly in astrocytes. β-Gal activity in J3T cells was also higher with the mCMV than the hCMV promoter driving tetracycline-dependent (TetON) transgene expression within high-capacity adenovirus vectors (HC-Ads). Dog glioma cells were efficiently transduced by HC-Ads expressing mCMV-driven HSV1-TK, which induced 90{\%} reduction in cell viability in the presence of ganciclovir. J3T cells were also effectively transduced with HC-Ads expressing Flt3L under the control of the regulatable TetON promoter system, and as predicted, Flt3L release was stringently inducer dependent. HC-Ads encoding therapeutic transgenes under the control of regulatory sequences driven by the mCMV promoter are excellent vectors for the treatment of spontaneous GBM in dogs, which constitute an ideal preclinical animal model.",
keywords = "Brain inflammation, Canine, Flt3L, Gene therapy, Glioma, Gutless adenoviral vectors, HSV1-TK",
author = "Marianela Candolfi and Pluhar, {G. Elizabeth} and Kurt Kroeger and Mariana Puntel and James Curtin and Carlos Barcia and Muhammad, {A. K M Ghulam} and Weidong Xiong and Chunyan Liu and Sonali Mondkar and William Kuoy and Terry Kang and McNeil, {Elizabeth A.} and Freese, {Andrew B.} and Ohlfest, {John R.} and Moore, {Peter F} and Donna Palmer and Phillip Ng and Young, {John D.} and Lowenstein, {Pedro R.} and Castro, {Maria G.}",
year = "2007",
month = "7",
doi = "10.1215/15228517-2007-012",
language = "English (US)",
volume = "9",
pages = "245--258",
journal = "Neuro-Oncology",
issn = "1522-8517",
publisher = "Oxford University Press",
number = "3",

}

TY - JOUR

T1 - Optimization of adenoviral vector-mediated transgene expression in the canine brain in vivo, and in canine glioma cells in vitro

AU - Candolfi, Marianela

AU - Pluhar, G. Elizabeth

AU - Kroeger, Kurt

AU - Puntel, Mariana

AU - Curtin, James

AU - Barcia, Carlos

AU - Muhammad, A. K M Ghulam

AU - Xiong, Weidong

AU - Liu, Chunyan

AU - Mondkar, Sonali

AU - Kuoy, William

AU - Kang, Terry

AU - McNeil, Elizabeth A.

AU - Freese, Andrew B.

AU - Ohlfest, John R.

AU - Moore, Peter F

AU - Palmer, Donna

AU - Ng, Phillip

AU - Young, John D.

AU - Lowenstein, Pedro R.

AU - Castro, Maria G.

PY - 2007/7

Y1 - 2007/7

N2 - Expression of the immune-stimulatory molecule Fms-like tyrosine kinase 3 ligand (Flt3L) and the conditional cytotoxic enzyme herpes simplex virus type 1 thymidine kinase (HSV1-TK) provides long-term immune-mediated survival of large glioblastoma multiforme (GBM) models in rodents. A limitation for predictive testing of novel antiglioma therapies has been the lack of a glioma model in a large animal. Dogs bearing spontaneous GBM may constitute an attractive large-animal model for GBM, which so far has remained underappreciated. In preparation for a clinical trial in dogs bearing spontaneous GBMs, we tested and optimized adenovirus-mediated transgene expression with negligible toxicity in the dog brain in vivo and in canine J3T glioma cells. Expression of the marker gene β-galactosidase (β-Gal) was higher when driven by the murine (m) than the human (h) cytomegalovirus (CMV) promoter in the dog brain in vivo, without enhanced inflammation. In the canine brain, β-Gal was expressed mostly in astrocytes. β-Gal activity in J3T cells was also higher with the mCMV than the hCMV promoter driving tetracycline-dependent (TetON) transgene expression within high-capacity adenovirus vectors (HC-Ads). Dog glioma cells were efficiently transduced by HC-Ads expressing mCMV-driven HSV1-TK, which induced 90% reduction in cell viability in the presence of ganciclovir. J3T cells were also effectively transduced with HC-Ads expressing Flt3L under the control of the regulatable TetON promoter system, and as predicted, Flt3L release was stringently inducer dependent. HC-Ads encoding therapeutic transgenes under the control of regulatory sequences driven by the mCMV promoter are excellent vectors for the treatment of spontaneous GBM in dogs, which constitute an ideal preclinical animal model.

AB - Expression of the immune-stimulatory molecule Fms-like tyrosine kinase 3 ligand (Flt3L) and the conditional cytotoxic enzyme herpes simplex virus type 1 thymidine kinase (HSV1-TK) provides long-term immune-mediated survival of large glioblastoma multiforme (GBM) models in rodents. A limitation for predictive testing of novel antiglioma therapies has been the lack of a glioma model in a large animal. Dogs bearing spontaneous GBM may constitute an attractive large-animal model for GBM, which so far has remained underappreciated. In preparation for a clinical trial in dogs bearing spontaneous GBMs, we tested and optimized adenovirus-mediated transgene expression with negligible toxicity in the dog brain in vivo and in canine J3T glioma cells. Expression of the marker gene β-galactosidase (β-Gal) was higher when driven by the murine (m) than the human (h) cytomegalovirus (CMV) promoter in the dog brain in vivo, without enhanced inflammation. In the canine brain, β-Gal was expressed mostly in astrocytes. β-Gal activity in J3T cells was also higher with the mCMV than the hCMV promoter driving tetracycline-dependent (TetON) transgene expression within high-capacity adenovirus vectors (HC-Ads). Dog glioma cells were efficiently transduced by HC-Ads expressing mCMV-driven HSV1-TK, which induced 90% reduction in cell viability in the presence of ganciclovir. J3T cells were also effectively transduced with HC-Ads expressing Flt3L under the control of the regulatable TetON promoter system, and as predicted, Flt3L release was stringently inducer dependent. HC-Ads encoding therapeutic transgenes under the control of regulatory sequences driven by the mCMV promoter are excellent vectors for the treatment of spontaneous GBM in dogs, which constitute an ideal preclinical animal model.

KW - Brain inflammation

KW - Canine

KW - Flt3L

KW - Gene therapy

KW - Glioma

KW - Gutless adenoviral vectors

KW - HSV1-TK

UR - http://www.scopus.com/inward/record.url?scp=34547445754&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34547445754&partnerID=8YFLogxK

U2 - 10.1215/15228517-2007-012

DO - 10.1215/15228517-2007-012

M3 - Article

C2 - 17522335

AN - SCOPUS:34547445754

VL - 9

SP - 245

EP - 258

JO - Neuro-Oncology

JF - Neuro-Oncology

SN - 1522-8517

IS - 3

ER -